Aktis Oncology (NASDAQ:AKTS – Get Free Report) shares reached a new 52-week high on Wednesday . The stock traded as high as $34.19 and last traded at $32.3590, with a volume of 1211861 shares changing hands. The stock had previously closed at $30.11.
Analyst Ratings Changes
AKTS has been the topic of several research reports. Raymond James Financial initiated coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective on the stock. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. William Blair initiated coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating on the stock. Finally, HC Wainwright upped their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.00.
Check Out Our Latest Report on Aktis Oncology
Aktis Oncology Trading Up 2.8%
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last posted its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.87 million for the quarter. On average, equities analysts predict that Aktis Oncology will post -1.62 EPS for the current year.
About Aktis Oncology
Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
Read More
- Five stocks we like better than Aktis Oncology
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
